Research Article

Effect of Yiqi Buxue Decoction on Hemodynamic Changes of the Uterine Artery and Fetal Umbilical Artery and Pregnancy Outcomes in Pregnant Patients with Pulmonary Arterial Hypertension

Rendong Han,1 Liya Gao,2 Hongbo Sun,2 Mei Li,2 and Chunxia Deng2

1Department of Obstetrics, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China
2Department of Gynecology and Obstetrics, Beijing ChuiYangLiu Hospital, Beijing 100022, China

Correspondence should be addressed to Chunxia Deng; zhangjiao27138487@163.com

Received 30 June 2021; Accepted 9 August 2021; Published 18 August 2021

Academic Editor: Muhammad Wasim Khan

Copyright © 2021 Rendong Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the effect of Yiqi Buxue decoction on hemodynamic changes of the uterine artery and fetal umbilical artery and pregnancy outcomes in pregnant patients with pulmonary arterial hypertension (PAH). Methods. 120 pregnant patients with PAH treated in our hospital (January 2019-January 2020) were chosen as the research objects, and randomly split into group A (n = 60) and group B (n = 60). Both groups received routine treatment, and group B was treated with sildenafil citrate, while group A was treated with Yiqi Buxue decoction combined with sildenafil citrate. Both groups received 6 weeks of treatment to analyze the hemodynamic changes of the uterine artery and fetal umbilical artery and compare the cardiopulmonary function indexes and pregnancy outcomes between the two groups. Results. The hemodynamic indexes of the uterine artery and fetal umbilical artery, cardiopulmonary function indexes, and pregnancy outcomes in group A after treatment were notably better compared with group B (P < 0.01). Conclusion. Yiqi Buxue decoction can stabilize the hemodynamics of pregnant patients with PAH, improve their cardiopulmonary function, alleviate hypotension, and thus, reduce the possibility of adverse pregnancy outcomes, which should be popularized in practice.

1. Introduction

Pulmonary hypertension (PAH) during pregnancy refers to structural and functional changes in the pulmonary vessels caused by nonspecific causes, which is mainly characterized by elevated pulmonary vascular resistance (PVR). With obvious hemodynamic abnormalities and significantly increased cardiac load, patients are prone to heart failure under the influence of physiological changes during pregnancy, which seriously threatens maternal and child health [1–3]. Studies have shown that PAH is one of the leading important causes of perinatal death in patients, accounting for 12% of all causes of maternal death. With the continuous optimization of medical technology in recent years, the perinatal mortality rate of PAH has decreased from 33%–42% to 4.2%–15.0% [4], indicating an increased survival rate of patients. However, for patients with Eisenmenger syndrome, the mortality rate remains about 25% [5, 6], suggesting a high possibility of adverse pregnancy outcomes. At present, Western medicine treatment is often adopted to improve the hemodynamics of patients in practice, and targeted PAH drugs are gradually introduced, including anticoagulant drugs such as sildenafil citrate to alleviate the hypercoagulable state of patients and enhance their cardiopulmonary function. However, most PAH drugs are expensive [7] and cannot be widely applied in the early stage of the disease, so it is extremely important to choose cheaper and more efficient drugs for treatment. Yiqi Buxue decoction is a common drug to regulate qi and blood in clinic, which is able to improve the obstructed blood flow of patients, reduce...
the vascular resistance, enhance the cardiopulmonary function, optimize the microcirculation, enhance the anti-hypoxia ability of tissue, and stabilize the patients’ internal environment. However, no research on the application of Yiqi Buxue decoction in PAH has been reported in academia. Based on this, Yiqi Buxue decoction was adopted in this paper for adjuvant treatment of PAH patients, summarized as follows.

2. Materials and Methods

2.1. General Information. The study is a randomized controlled trial. One hundred and twenty pregnant patients with PAH treated in Beijing ChuiYangLiu Hospital (January 2019-January 2020) were chosen as the research objects and randomly split into group A (n = 60) and group B (n = 60). No statistical difference was found in general information between the two groups (P > 0.05; Table 1). This study was approved by the hospital ethics committee, and all experiments conformed to the provisions of the Declaration of Helsinki.

2.2. Inclusion Criteria. The inclusion criteria of this study were as follows. (1) The patients or their families fully recognized the study process and signed the informed consent; (2) the patients were diagnosed with PAH during pregnancy after examination, according to the diagnostic criteria of ESC/ERS Pulmonary Hypertension Guidelines [8, 9]; and (3) the patients did not receive relevant treatment before enrollment [10, 11].

2.3. Exclusion Criteria. The exclusion criteria for patients in this study were as follows. (1) The patients had mental problems or could not communicate with others; (2) the patients had other organic diseases; (3) the patients were complicated with preeclampsia, endocrine system diseases, and other diseases; (4) the patients had chronic hypertension; and (5) the patients had placenta previa, or the fetuses had congenital malformation.

3. Methods

The patients in both groups received routine treatment, including introducing a low-salt and healthy diet, performing oxygen inhalation and cardiotoxic treatment, limiting their physical activity of the patients, and arranging reasonable daily work for them. In addition, group B was treated with sildenafil citrate, while group A was treated with Yiqi Buxue decoction combined with sildenafil citrate. Both groups received 6 weeks of treatment, specifically as follows. (1) Sildenafil citrate: the patients took sildenafil citrate daily (Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Baiyunshan Pharmaceutical General Factory; NMPA approval no. H20143255) before meals, 3 times a day and 25 mg each time. (2) Yiqi Buxue decoction: the decoction included 15 g of Codonopsis pilosula, 15 g of Astragalus membranaceus, 10 g of Angelica sinensis, 10 g of Ligusticum wallichii, 10 g of Radix Paeoniae Alba, 10 g of prepared Rehmannia root, 10 g of Poria cocos, 10 g of Chinese yam, 10 g of motherwort, and 5 g of liquorice. The drugs were decocted in warm water, and the decoction was taken with one dose a day after breakfast and dinner.

3.1. Observation Criteria.

(1) Hemodynamic changes of the uterine artery and fetal umbilical artery: all patients were examined by using a color Doppler ultrasound (Color ultrasound diagnostic instrument Voluson P6 produced by GE Healthcare; NMPA certified no. 20152062178) before and after treatment. With the probe frequency of 3 MHz and pulse sampling volume of 2 mm, the two-dimensional ultrasound diagnostic instrument was placed at the distal branch of the internal iliac artery to position the uterine artery and at 4 cm from the placenta to position the umbilical artery. Three stable arterial blood flow spectra were continuously measured to record the pulsatility index (PI), resistance index (RI), and the ratio of peak systolic velocity (S) to end-diastolic peak velocity (D) of the uterine artery and fetal umbilical artery.

(2) Cardiopulmonary function indexes: fasting arterial blood and central venous blood were collected before and after treatment. Arterial oxygen saturation and arterial oxygen partial pressure were measured. The D-dimer level was detected by immuno-turbidimetry (kits: Nanjing Getein Biotechnology Co., Ltd., Jiangsu Medical Products Administration No. 2400146). The level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was detected by radioimmunoassay (Cobase 411 electrochemiluminescence instrument with matching reagent; NMPA certified no. 3402843).

(3) Pregnancy outcomes: pregnancy outcomes included fetal pregnancy outcomes and patient pregnancy outcomes. The number of adverse pregnancy outcomes was recorded.

3.2. Statistical Treatment. In this study, the data were processed by SPSS20.0 software and graphed by GraphPad Prism 7 (GraphPad Software, San Diego, USA). The data included enumeration data and measurement data, tested by the X² and t-test. The differences were statistically significant when P < 0.05.

4. Results

4.1. Comparison of Hemodynamic Changes of the Uterine Artery and Fetal Umbilical Artery. After treatment, the hemodynamics indexes of the uterine artery and fetal umbilical artery in group A were notably better compared with those in group B (P < 0.001; Figures 1 and 2).
4.2. Comparison of Cardiopulmonary Function Indexes.
The cardiopulmonary function indexes of group A after treatment were notably better compared with those of group B \((P < 0.001; \text{Table 2}).\)

4.3. Comparison of Pregnancy Outcomes. The pregnancy outcomes in group A were notably better compared with those in group B \((P < 0.001; \text{Table 3}).\)

5. Discussion

Occurring mostly in women of childbearing age, PAH will cause intimal hyperplasia of the pulmonary arteries, autotochthonous thrombus, and increased pulmonary vascular resistance, ultimately increasing the right heart load of patients and leading to heart failure or death in severe cases. Both secondary PAH and primary PAH are absolute contraindications of pregnancy because patients in pregnancy will undergo a series of physiological changes that will greatly increase the mortality and the incidence of adverse pregnancy outcomes [6, 12–14]. For the patients, changes during pregnancy include increased blood volume, physiological anemia, the abnormal cardiac output that can increase by about 50%, and a hypercoagulable state in the body of patients. In the third trimester, the returned blood volume of patients significantly decreases, significantly increasing the possibility of heart failure or death [15–17]. For the fetuses, PAH can reduce the placental blood perfusion. Imaging examination often shows increased resistance of the uterine artery and umbilical artery, so the fetuses cannot obtain nutrition from the placenta and suffer from long-term chronic hypoxia with the mothers, which seriously affects their life health. In this study, the results showed that the hemodynamics indexes of uterine artery and fetal umbilical artery in group A were notably better compared with those in group B after treatment. Yiqi Buxue decoction has been found to have the function to resist platelet aggregation and reduce vascular resistance [18]. Therefore, it suggested that Yiqi Buxue decoction could effectively improve the hemodynamics of the patient.

Due to the high risk of pregnant patients with PAH, clinical practice has been promoting contraception knowledge of PAH women, while improving PAH treatment methods [19]. Since 1990, some progress has been made in the treatment of PAH in China, and the mortality rate of patients with mild PAH has currently decreased to less than 10%, but the prognosis of

| Items                              | Group A \((n = 60)\) | Group B \((n = 60)\) | \(X^2/t\) | \(P\)  |
|------------------------------------|----------------------|----------------------|-----------|-------|
| **Age (years)**                    | 20–45                | 21–45                |           |       |
| **Average age**                    | 32.98 ± 5.68         | 32.15 ± 5.98         | 0.780     | 0.437 |
| **Gestational age (weeks)**        | 6–37                 | 6–38                 |           |       |
| **Average gestational age**        | 33.26 ± 5.98         | 33.45 ± 5.24         | 0.185     | 0.854 |
| **Number of multiparous**          | 21                   | 20                   | 0.037     | 0.847 |
| **Number of primiparous**          | 39                   | 40                   |           |       |
| **Causes of PAH**                  |                      |                      |           |       |
| Congenital heart disease (CHD)     | 25                   | 24                   | 0.035     | 0.853 |
| Rheumatic heart disease (RHD)      | 15                   | 16                   | 0.044     | 0.835 |
| Hypertensive heart disease (HHD)   | 10                   | 12                   | 0.223     | 0.637 |
| Other                              | 10                   | 8                    | 0.261     | 0.609 |
| **Number of fetus**                |                      |                      | 0.261     | 0.609 |
| Single birth                       | 50                   | 52                   |           |       |
| Multiple birth                     | 10                   | 8                    |           |       |
| **Number of patients who received cardiac therapy** | 2      | 3       | 0.209 | 0.648 |
| Residence                          |                      |                      | 0.040     | 0.841 |
| Urban area                         | 42                   | 43                   |           |       |
| Rural area                         | 18                   | 17                   |           |       |
| **Monthly income (yuan)**          |                      |                      |           |       |
| ≥4000                              | 36                   | 37                   | 0.035     | 0.852 |
| <4000                              | 24                   | 23                   |           |       |
| **PAH degree**                     |                      |                      |           |       |
| Mild                               | 38                   | 40                   | 0.147     | 0.702 |
| Moderate                           | 16                   | 15                   | 0.044     | 0.835 |
| Severe                             | 6                    | 5                    | 0.100     | 0.752 |
| Education                          |                      |                      | 0.139     | 0.709 |
| Senior high school and below       | 25                   | 23                   |           |       |
| University and above               | 35                   | 37                   |           |       |
patients with severe PAH remains unsatisfactory [20]. Although studies have shown that medication from early pregnancy can optimize the microcirculation of patients, drugs such as endothelin antagonists leave adverse effects on mothers and fetuses and cannot effectively improve maternal and fetal outcomes [21]. Sildenafil citrate selected in this study is a drug to treat PAH with high safety, which can reduce the hypoxemia of patients and optimize their cardiopulmonary function. Therefore, the results showed that the cardiopulmonary indexes and oxygen saturation of both groups were improved, indicating that the maternal and fetal hypoxia was alleviated. Based on this, group A was additionally treated with Yiqi Buxue decoction that contained Astragalus membranaceus, Angelica sinensis, Poria cocos, motherwort, and Ligusticum wallichii. Among them, Astragalus membranaceus can resist platelet aggregation, reduce vascular resistance, enhance the pulmonary ventilation function, and boost the cardiopulmonary function of patients, thus improving their oxygen utilization and antihypoxia ability [22, 23]. Angelica sinensis can alleviate tissue damage caused by ischemia, reduce blood
viscosity, and play a positive role in replenishing qi and enriching the blood. *Poria cocos* and motherwort promote blood circulation to remove blood stasis, with the effects of detumescence and diuresis. Therefore, group A after treatment had a lower D-dimer level and notably better microcirculation compared with group B. This demonstrated that the hemodynamic changes of the uterine artery and umbilical artery in group A were better, so the fetuses could obtain a stable source of nutrients, thus reducing the chance of low-birth-weight newborns. Zhu et al. have found that ligustrazine not only has a good effect of dilating arteries and reducing the pulmonary arterial pressure of PAH patients but also has an antioxidant effect to scavenge oxygen free radicals and reduce the NT-proBNP level [24]. NT-proBNP, a common evaluation index of cardiac function in clinic, is positively correlated with pulmonary arterial pressure, so the decreased NT-proBNP indicated a lower degree of PAH in patients. Therefore, the lower NT-proBNP in group A represented more obvious improvement of PAH and a lower risk of patients during pregnancy. In addition, *Ligusticum wallichii* can alleviate pulmonary arteriospasm and further increase the placental blood supply and oxygen transportation by optimizing the blood circulation.

**Figure 2: Comparison of hemodynamic changes in the fetal umbilical artery (X ± s).** The abscissa represents before and after treatment. The black area is group A, and the gray area is group B. (a) The umbilical artery PI. With no statistical difference in the PI between the two groups before treatment (0.96 ± 0.05 and 0.97 ± 0.06, *P* > 0.05), the PI in group A after treatment was notably lower compared with that in group B (0.85 ± 0.04 and 0.92 ± 0.06, *P* < 0.001). (b) The umbilical artery RI. With no statistical difference in the RI between the two groups before treatment (0.70 ± 0.06 and 0.69 ± 0.05, *P* > 0.05), the RI in group A after treatment was notably lower compared with that in group B (0.55 ± 0.06 and 0.63 ± 0.04, *P* < 0.001). (c) Umbilical artery S/D. With no statistical difference in the S/D between the two groups before treatment (2.67 ± 0.15 and 2.68 ± 0.14, *P* > 0.05), the S/D in group A after treatment was notably lower compared with that in group B (2.48 ± 0.15 and 2.59 ± 0.12, *P* < 0.001).
making the fetuses less likely to suffer from intrauterine distress or asphyxia and comprehensively reducing the adverse effect of PAH on the fetuses.

The results showed that Yiqi Buxue decoction could be taken in the early pregnancy to reduce the negative effect of physiological changes during pregnancy on PAH patients. However, the patients were not grouped in detail according to the gestational age in this study. Whether the patients can take Yiqi Buxue decoction alone, whether they can take it throughout the pregnancy, and its effect on different gestational weeks still need to be further explored.

In conclusion, Yiqi Buxue decoction can stabilize the hemodynamics of pregnant patients with PAH, improve their cardiopulmonary function, alleviate hypotension, and thus, reduce the possibility of adverse pregnancy outcomes, which should be popularized in practice.

Data Availability

All data can be obtained from the corresponding authors.

Consent

Consent was not applicable for this study.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Rendong Han and Liya Gao contributed equally to this article.

References

[1] A. H. Weldegerima, "Outcome of pulmonary hypertension in pregnancy: experience from resource limited setting in a university hospital in northern ethiopia," Cardiovascular Journal of Africa, vol. 29, 2018.
[2] J. Guglielminotti, R. Landau, A. M. Friedman et al., “Pulmonary hypertension during pregnancy in New York state,” Maternal and Child Health Journal, vol. 2003–2014, 2018.

[3] Y. P. Gong, "Clinical characteristics and pregnancy-outcomes in parturients with pulmonary hypertension: experience with 39 consecutive cases from China," Clinical & Experimental Obstetrics & Gynecology, vol. 45, no. 2, 2018.

[4] S. S. Moni and S. Murthy, "Pulmonary hypertension in pregnancy," Clinical Obstetrics and Gynecology, vol. 134, 2020.

[5] V. Franco, J. J. Ryan, and V. V. McLaughlin, "Pulmonary hypertension in women," Heart Failure Clinics, vol. 15, no. 1, pp. 137–145, 2019.

[6] N. Jha, A. K. Jha, S. K. Mishra et al., “Pulmonary hypertension and pregnancy outcomes: systematic review and meta-analysis,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 253, 2020.

[7] A. Keepanasseril, A. A. Pillai, J. Yavanarsiya et al., “Outcome of pregnancies in women with pulmonary hypertension: a single-centre experience from South India,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 126, 2019.

[8] Z. Y. Vasquez-Ortiz, R. Gonzalez-Varela, G. J. Navarrete et al., “P626 Peripartum cardiomyopathy with persistent ventricular dysfunction and intracavitary thrombosis despite treatment with dopamine receptors agonist. The role of the three-dimensional echocardiography,” European Heart Journal-Cardiovascular Imaging, 2020.

[9] M. Ladouceur, L. Benoit, A. Basquin et al., “Maternal and fetal outcome in patients with cyanotic congenital heart disease: a multicenter observational study,” Archives of Cardiovascular Diseases Supplements, vol. 10, no. 1, p. 134, 2018.

[10] A. J. Schissler, R. J. Glyn, P. S. Sobieszczyk et al., “Ultrasound-assisted catheter-directed thrombolysis compared with anticoagulation alone for treatment of intermediate-risk pulmonary embolism,” Pulmonary Circulation, vol. 8, no. 4, 2018.

[11] J. Baghel, A. Keepanasseril, A. A. Pillai et al., “Prediction of adverse cardiac events in pregnant women with valvular rheumatic heart disease,” Heart, vol. 106, 2020.

[12] B. J. Voskamp, M. Peelen, A. Ravelli et al., “Association between fetal sex, birthweight percentile and adverse pregnancy outcome,” Acta Obstetricia et Gynecologica Scandinavica, vol. 99, no. 20, 2019.

[13] I. Singh, E. Horn, and J. Haythe, “Pulmonary hypertension in pregnancy,” Clinics in Chest Medicine, vol. 42, no. 9, 2021.

[14] A. Keepanasseril, “Outcome of pregnancies in women with pulmonary hypertension: a single centre experience from South India,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 126, 2019.

[15] G. Kope, M. D. W. Magoń, J. Stpniewski et al., “Pregnancy in a patient with chronic thromboembolic pulmonary hypertension after successful treatment with balloon pulmonary angioplasty,” Canadian Journal of Cardiology, vol. 36, no. 4, 2020.

[16] J. B. Badlam, D. B. Badesch, E. D. Austin et al., “United States pulmonary hypertension scientific registry (USPHSR): baseline characteristics,” Chest, vol. 159, 2020.

[17] L. Valko, G. Czosza, A. Merei et al., “Management of acutely decompensated chronic thromboembolic pulmonary hypertension in late pregnancy: a case report,” BMC Pregnancy and Childbirth, vol. 19, no. 1, 2019.

[18] S. Adachi, S. Shimokata, M. Yoshida et al., “Addition of a bilateral access form of peripheral extracorporeal membrane oxygenation rescued a patient with idiopathic pulmonary arterial hypertension who developed circulatory collapse immediately after childbirth,” Pulmonary Circulation, vol. 10, no. 1, 2020.

[19] H. Saavedra, C. Toncel, V. Delgado et al., “Reversible pulmonary hypertension and high-output heart failure triggered by pregnancy in a patient with congenital arteriovenous malformation: a case report,” Obstetric Medicine, vol. 12, no. 2, 2019.

[20] A. B. Hartopo, D. W. Anggrahini, D. S. Nurdiani et al., “Severe pulmonary hypertension and reduced right ventricle systolic function associated with maternal mortality in pregnant uncorrected congenital heart diseases,” Pulmonary Circulation, vol. 9, no. 4, 2019.

[21] F. Rashidi and H. Sate, “Pregnancy outcome in a pregnant patient with idiopathic Pulmonary Arterial Hypertension: a case report and review of the literature,” Journal of Medical Case Reports, vol. 12, no. 1, p. 31, 2018.

[22] C. Hohmann, D. Dumitrescu, F. Gerhardt et al., “EXPRESS: high-risk pregnancy in a patient with pulmonary arterial hypertension due to congenital heart disease (PAH-CHD) with temporary shunt inversion and deoxygenation,” Pulmonary Circulation, vol. 9, 2019.

[23] A. Vorakamol, P. Phoophiboon, P. Nattapong et al., “Successful multimodality management of severe pulmonary arterial hypertension during pregnancy with VA-ECMO and atrial septostomy using stent,” BMJ case reports, vol. 12, no. 12, 2019.

[24] C. X. Zhu, X. Wei, H. Q. Chen et al., “Obstetric outcomes in pregnancy with pulmonary hypertension: a retrospective study of 78 cases at one center,” Journal of Obstetrics and Gynaecology Research, vol. 44, 2018.